Immunovant, Inc.
- Last sale
- Nov 12, 2026 · -5.35%
- Market cap
- $7.25B
- 206.95M shares
- Filings
- 653
—
—
—Q2 2027N/M FY26 yoy
Q3 2019
—FY 2026derivedN/M FY26 yoy
Q2 2027N/M FY26 yoy
Q2 2027+26.4% FY26 yoy
- $7.25B
- —
- —
- 11.0×
- -5.62%
- —
FY2026 figures · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Net Interest Income
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2024 | 2024-03-31 | $24,948,000 | reported | |
| FY 2023 | 2023-03-31 | $7,578,000 | reported | |
| FY 2022 | 2022-03-31 | $0 | reported |
Biological products, except diagnostic substances
Immunovant, Inc. is the 17th largest of the 176 covered companies the SEC files under this code, by market cap. SIC 2836
CompanyRevenueGrowthNet marginMarket cap
RGENRepligen Corp$738.3M16.4%6.6%$10.7BPCVXVaxcyte, Inc.———$10.2BKRYSKrystal Biotech, Inc.$389.1M33.9%52.6%$9.1B
IMVTImmunovant, Inc. (this company)———$7.3B
TWSTTwist Bioscience Corp$376.6M20.3%20.6%$7.2BKODKodiak Sciences Inc.———$7.1BCGONCG Oncology, Inc.$4.0M254.7%3,985.0%$6.8BIBRXImmunityBio, Inc.$113.3M668.3%310.2%$6.5BSRRKScholar Rock Holding Corp$0.0——$5.3BPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in market cap first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Immunovant, Inc. · CIK 1764013 · Engraved from SEC EDGAR